Developer docs
API playgroundTry for free, no card

Search company profiles

MultiCASE

Full company profile

uuid000hsx7

Namestring
MultiCASE
Legal namestring
MultiCASE, Inc.
Websiteurl
multicase.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

MultiCASE is a privately held US software company headquartered in Mayfield Heights, Ohio, specializing in computational toxicology and in silico chemical safety assessment. Founded in 1996 according to firmographic records, the company develops proprietary QSAR (Quantitative Structure-Activity Relationship) modeling software that uses machine learning to predict chemical toxicity endpoints from molecular structure, primarily serving pharmaceutical companies for drug safety evaluation, regulatory submissions, and chemical hazard screening.

The product portfolio centers on three software platforms: CASE Ultra, a desktop application for in silico toxicity prediction and risk assessment; QSAR Flex, a flexible QSAR modeling platform that was transitioned to a web-accessible application in 2026; and META Ultra, a meta-analysis tool for integrating multiple toxicity prediction methods and curated data sources. Alongside the software, MultiCASE provides specialized assessment services covering ICH M7 mutagenicity compliance, nitrosamine carcinogenicity evaluation, and early-stage research screening. The technology stack uses proprietary QSAR models with original research underway on LLM-assisted expert review of bacterial mutagenicity predictions under ICH M7.

MultiCASE generates revenue primarily through recurring software licensing of its proprietary platforms to enterprise customers in pharmaceutical and chemical safety, operating a direct enterprise field-sales motion with free trial offers and supplementing US direct sales with a network of distribution partners covering Brazil, China, India, Japan, Korea, Mexico, and Latin America. Pricing is not publicly disclosed. The firm is identified as a key player in the global Computational Toxicology Solutions market, operating alongside larger peers including Instem (Leadscope), Lhasa Limited, Inotiv, Simulations Plus, and Schrodinger, with a lean 1-10 employee organizational structure funded organically across nearly thirty years of continuous operation.

Short descriptiontext

MultiCASE is a privately held Ohio-based software company that develops proprietary QSAR machine-learning platforms for in silico chemical toxicity prediction, serving pharmaceutical companies for ICH M7 mutagenicity compliance, nitrosamine evaluation, and drug safety regulatory submissions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in silico toxicology, QSAR modeling software, chemical safety assessment, computational toxicology, drug safety prediction
Industry4 codes
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAGAFAE
Genetic Toxicology (Ames/Micronucleus/Comet)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Computational Toxicology Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Licensing
TypeSubscription Recurring
Description

MultiCASE generates revenue through licensing its proprietary software products including CASE Ultra, QSAR Flex, and META Ultra. These are offered as desktop and web-based applications for in silico toxicity evaluations and chemical safety assessment.

multicase.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1CASE Ultra
Description

Software for in silico risk assessments and chemical safety evaluation

multicase.com
+2 more records
Core offering1 text field

MultiCASE develops and licenses proprietary software for in silico toxicity prediction and chemical safety assessment used by pharmaceutical and chemical safety organizations. Its portfolio includes three core software products — CASE Ultra (desktop), QSAR Flex (web-based), and META Ultra (meta-analysis) — built on proprietary QSAR models and AI/ML to predict endpoints such as mutagenicity, carcinogenicity, and bioavailability, with specialized assessment services for ICH M7 compliance and nitrosamine evaluation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MultiCASE provides a software platform for in silico toxicity evaluation and chemical safety assessment. The portfolio consists of three core software products (CASE Ultra, QSAR Flex, and META Ultra) designed to strengthen risk assessment strategies, along with specialized assessment services covering ICH M7 compliance, nitrosamine evaluation, and early-stage research applications. The software utilizes proprietary QSAR models to predict chemical toxicity endpoints for regulatory and pharmaceutical applications.

Product and service6 records
1CASE Ultra
CategoryIn Silico Toxicology Software
2QSAR Flex
CategoryQSAR Modeling Software
3META Ultra
4ICH M7 Assessment
5Nitrosamine Evaluation
6Early Stage Research
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Regional Distribution Partners (Brazil, China, India, Japan, Korea, Mexico, Latin America)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

MultiCASE works with established and dependable distribution partners to support their global user base in Brazil, China, India, Japan, Korea, Mexico and Latin America regions.

multicase.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public computational chemistry and molecular simulation platform company with LiveDesign and broader drug discovery suite. Significantly larger, broader incumbent that includes computational toxicology capabilities adjacent to MultiCASE's niche.

TypeBroad incumbent
Description

Public company offering broader computational chemistry, PBPK modeling (GastroPlus), and toxicology software (ADMETPredictor). Larger, broader portfolio competitor that overlaps with MultiCASE on QSAR/ADMET prediction.

TypeEmerging player
Description

Cheminformatics platform provider with chemical structure handling, property prediction, and drug discovery software. Adjacent peer serving similar pharma/chemistry customers with overlapping computational chemistry capabilities.

TypeDirect peer
Description

Not-for-profit organization providing in silico toxicology software (Derek Nexus, Sarah Nexus) for ICH M7 mutagenicity and impurity assessment. Direct competitor in the same regulatory toxicology niche with a similar member-funded distribution model.

TypeDirect peer
Description

Instem acquired Leadscope, a direct computational toxicology and QSAR software provider. Most directly comparable peer — same in silico toxicology customer base (pharma/regulatory), overlapping product functionality, and same ICH M7 use cases.

TypeEmerging player
Description

AI-driven drug discovery company using computational methods for small molecule design. Adjacent peer — listed alongside MultiCASE as a key player; shares AI-in-pharma positioning but focuses on discovery rather than safety assessment.

TypeBroad incumbent
Description

Preclinical contract research organization providing toxicology and safety assessment services alongside software-enabled offerings. Listed alongside MultiCASE as a key player in computational toxicology solutions.

TypeEmerging player
Description

Chemical compound sourcing and informatics platform. Adjacent to MultiCASE's chemistry-data workflow; serves overlapping pharma/cheminformatics buyer personas but focuses on compound supply rather than toxicity prediction.

TypeDirect peer
Description

Provider of chemistry software including predictive ADMET and toxicity modules for pharma and chemical safety. Comparable peer offering in silico property/toxicity prediction tools to similar enterprise customers.

TypeRegional player
Description

Toxicology-focused CRO offering in vitro and in silico toxicology services including ToxTracker. Comparable in the toxicology services space with EMEA focus; serves overlapping pharma safety assessment customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MultiCASE

Computational Toxicology Softwaremulticase.com

MultiCASE is a privately held Ohio-based software company that develops proprietary QSAR machine-learning platforms for in silico chemical toxicity prediction, serving pharmaceutical companies for ICH M7 mutagenicity compliance, nitrosamine evaluation, and drug safety regulatory submissions.

What MultiCASE does

MultiCASE is a privately held US software company headquartered in Mayfield Heights, Ohio, specializing in computational toxicology and in silico chemical safety assessment. Founded in 1996 according to firmographic records, the company develops proprietary QSAR (Quantitative Structure-Activity Relationship) modeling software that uses machine learning to predict chemical toxicity endpoints from molecular structure, primarily serving pharmaceutical companies for drug safety evaluation, regulatory submissions, and chemical hazard screening.

The product portfolio centers on three software platforms: CASE Ultra, a desktop application for in silico toxicity prediction and risk assessment; QSAR Flex, a flexible QSAR modeling platform that was transitioned to a web-accessible application in 2026; and META Ultra, a meta-analysis tool for integrating multiple toxicity prediction methods and curated data sources. Alongside the software, MultiCASE provides specialized assessment services covering ICH M7 mutagenicity compliance, nitrosamine carcinogenicity evaluation, and early-stage research screening. The technology stack uses proprietary QSAR models with original research underway on LLM-assisted expert review of bacterial mutagenicity predictions under ICH M7.

MultiCASE generates revenue primarily through recurring software licensing of its proprietary platforms to enterprise customers in pharmaceutical and chemical safety, operating a direct enterprise field-sales motion with free trial offers and supplementing US direct sales with a network of distribution partners covering Brazil, China, India, Japan, Korea, Mexico, and Latin America. Pricing is not publicly disclosed. The firm is identified as a key player in the global Computational Toxicology Solutions market, operating alongside larger peers including Instem (Leadscope), Lhasa Limited, Inotiv, Simulations Plus, and Schrodinger, with a lean 1-10 employee organizational structure funded organically across nearly thirty years of continuous operation.

MultiCASE firmographics

Firmographics
Name
MultiCASE
Legal name
MultiCASE, Inc.
Website
https://multicase.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
MultiCASE is a privately held Ohio-based software company that develops proprietary QSAR machine-learning platforms for in silico chemical toxicity prediction, serving pharmaceutical companies for ICH M7 mutagenicity compliance, nitrosamine evaluation, and drug safety regulatory submissions.
Ownership category
akta.pro rank

MultiCASE industry classification

Industry
Product category
Computational Toxicology Software
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAGAFAE
Genetic Toxicology (Ames/Micronucleus/Comet)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • In silico toxicology
  • QSAR modeling software
  • Chemical safety assessment
  • Computational toxicology
  • Drug safety prediction

Where MultiCASE is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MultiCASE business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Licensing: MultiCASE generates revenue through licensing its proprietary software products including CASE Ultra, QSAR Flex, and META Ultra. These are offered as desktop and web-based applications for in silico toxicity evaluations and chemical safety assessment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

MultiCASE product offering

Product offering

Core offering

MultiCASE develops and licenses proprietary software for in silico toxicity prediction and chemical safety assessment used by pharmaceutical and chemical safety organizations. Its portfolio includes three core software products — CASE Ultra (desktop), QSAR Flex (web-based), and META Ultra (meta-analysis) — built on proprietary QSAR models and AI/ML to predict endpoints such as mutagenicity, carcinogenicity, and bioavailability, with specialized assessment services for ICH M7 compliance and nitrosamine evaluation.

Product overview

MultiCASE provides a software platform for in silico toxicity evaluation and chemical safety assessment. The portfolio consists of three core software products (CASE Ultra, QSAR Flex, and META Ultra) designed to strengthen risk assessment strategies, along with specialized assessment services covering ICH M7 compliance, nitrosamine evaluation, and early-stage research applications. The software utilizes proprietary QSAR models to predict chemical toxicity endpoints for regulatory and pharmaceutical applications.

Differentiator

Problem solved

Functional benefit

Brands

  • CASE Ultra: Software for in silico risk assessments and chemical safety evaluation
  • QSAR Flex
  • META Ultra

Products and services

  • CASE Ultra
  • QSAR Flex
  • META Ultra
  • ICH M7 Assessment
  • Nitrosamine Evaluation
  • Early Stage Research

Companies that use MultiCASE

Customer profile

Segments2 records

Ideal customer profiles2 records

MultiCASE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

MultiCASE partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Regional Distribution Partners (Brazil, China, India, Japan, Korea, Mexico, Latin America)minorChannel Partner/ Reseller/ DistributorMultiCASE works with established and dependable distribution partners to support their global user base in Brazil, China, India, Japan, Korea, Mexico and Latin America regions.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

MultiCASE competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Public computational chemistry and molecular simulation platform company with LiveDesign and broader drug discovery suite. Significantly larger, broader incumbent that includes computational toxicology capabilities adjacent to MultiCASE's niche.
  • Simulations Plus: Public company offering broader computational chemistry, PBPK modeling (GastroPlus), and toxicology software (ADMETPredictor). Larger, broader portfolio competitor that overlaps with MultiCASE on QSAR/ADMET prediction.
  • Inotiv: Preclinical contract research organization providing toxicology and safety assessment services alongside software-enabled offerings. Listed alongside MultiCASE as a key player in computational toxicology solutions.

Emerging players

  • ChemAxon: Cheminformatics platform provider with chemical structure handling, property prediction, and drug discovery software. Adjacent peer serving similar pharma/chemistry customers with overlapping computational chemistry capabilities.
  • Exscientia: AI-driven drug discovery company using computational methods for small molecule design. Adjacent peer — listed alongside MultiCASE as a key player; shares AI-in-pharma positioning but focuses on discovery rather than safety assessment.
  • MolPort: Chemical compound sourcing and informatics platform. Adjacent to MultiCASE's chemistry-data workflow; serves overlapping pharma/cheminformatics buyer personas but focuses on compound supply rather than toxicity prediction.

Direct peers

  • Lhasa Limited: Not-for-profit organization providing in silico toxicology software (Derek Nexus, Sarah Nexus) for ICH M7 mutagenicity and impurity assessment. Direct competitor in the same regulatory toxicology niche with a similar member-funded distribution model.
  • Instem (Leadscope): Instem acquired Leadscope, a direct computational toxicology and QSAR software provider. Most directly comparable peer — same in silico toxicology customer base (pharma/regulatory), overlapping product functionality, and same ICH M7 use cases.
  • ACD/Labs (Advanced Chemistry Development): Provider of chemistry software including predictive ADMET and toxicity modules for pharma and chemical safety. Comparable peer offering in silico property/toxicity prediction tools to similar enterprise customers.

Regional players

  • Toxys: Toxicology-focused CRO offering in vitro and in silico toxicology services including ToxTracker. Comparable in the toxicology services space with EMEA focus; serves overlapping pharma safety assessment customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MultiCASE social profiles

Digital presence

MultiCASE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MultiCASE leadership team

Management profile

Number of profiles

MultiCASE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MultiCASE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MultiCASE

What does MultiCASE do?

MultiCASE develops and licenses proprietary software for in silico toxicity prediction and chemical safety assessment used by pharmaceutical and chemical safety organizations. Its portfolio includes three core software products — CASE Ultra (desktop), QSAR Flex (web-based), and META Ultra (meta-analysis) — built on proprietary QSAR models and AI/ML to predict endpoints such as mutagenicity, carcinogenicity, and bioavailability, with specialized assessment services for ICH M7 compliance and nitrosamine evaluation.

Is MultiCASE a public or private company?

MultiCASE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MultiCASE founded?

MultiCASE was founded in 1996. It employs 11 to 50 people.

Where is MultiCASE based?

MultiCASE is headquartered in Cleveland, United States, in the North America region.

How does MultiCASE make money?

One revenue line is on record: software Licensing.

Who are MultiCASE's main competitors?

Broad incumbents on record are Schrödinger, Simulations Plus and Inotiv. Emerging players are ChemAxon, Exscientia and MolPort. Direct peers are Lhasa Limited, Instem (Leadscope) and ACD/Labs (Advanced Chemistry Development). Toxys is listed as a regional player.

Does MultiCASE have an API?

No public API is recorded for MultiCASE.

What industry is MultiCASE in?

MultiCASE's product category is Computational Toxicology Software. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals